公开(公告)号：US20210338684A1

公开(公告)日：2021-11-04

申请号：US17370721

申请日：2021-07-08

Applicant: Genentech, Inc.

Inventor： Robert L. YAUCH ,  Xiaofen YE ,  Thomas E. JANUARIO

IPC: A61K31/5377 ,  A61P35/00 ,  A61K45/06 ,  C12Q1/6886

Abstract: The present invention provides diagnostic and therapeutic methods for cancer. The invention provides methods of determining whether a patient having a cancer is likely to respond to treatment comprising an inhibitor of H3K27 methylation, methods of predicting responsiveness of a patient having a cancer to treatment comprising one or more inhibitors of H3K27 methylation, methods of selecting a therapy for a patient having a cancer, and methods of treating cancer based on expression levels of biomarkers of the invention (e.g., the expression level of SMARCA2 or the occupancy level of H3K27 at a SMARCA2 promoter).

公开(公告)号：US20160250287A1

公开(公告)日：2016-09-01

申请号：US15029960

申请日：2014-03-06

Applicant: GENENTECH, INC.

Inventor： Robert L. YAUCH ,  Xiaofen YE ,  Avi ASHKENAZI

IPC: A61K38/17 ,  A61K45/06 ,  A61K31/5377 ,  A61K31/519 ,  A61K31/517

CPC classification number: A61K38/179 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K45/06 ,  A61K2300/00

Abstract: Provided herein are combination therapies for the treatment of pathological conditions, such as cancer, using an antagonist of FGFR signaling.

Abstract translation: 本文提供了使用FGFR信号传导的拮抗剂治疗病理状况如癌症的组合疗法。